These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

435 related articles for article (PubMed ID: 31698328)

  • 1. Safety and effectiveness of regorafenib in patients with metastatic colorectal cancer in routine clinical practice in the prospective, observational CORRELATE study.
    Ducreux M; Petersen LN; Öhler L; Bergamo F; Metges JP; de Groot JW; Wang JY; García Paredes B; Dochy E; Fiala-Buskies S; Cervantes A; O'Connor JM; Falcone A;
    Eur J Cancer; 2019 Dec; 123():146-154. PubMed ID: 31698328
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and Safety of Regorafenib With 2/1 Schedule for Patients ≥ 75 Years With Metastatic Colorectal Cancer (mCRC) After Failure of 2 Lines of Chemotherapy.
    Petrioli R; Chirra M; Messuti L; Fiaschi AI; Savelli V; Martellucci I; Francini E
    Clin Colorectal Cancer; 2018 Dec; 17(4):307-312. PubMed ID: 29548772
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Regorafenib for Patients with Metastatic Colorectal Cancer Who Progressed After Standard Therapy: Results of the Large, Single-Arm, Open-Label Phase IIIb CONSIGN Study.
    Van Cutsem E; Martinelli E; Cascinu S; Sobrero A; Banzi M; Seitz JF; Barone C; Ychou M; Peeters M; Brenner B; Hofheinz RD; Maiello E; André T; Spallanzani A; Garcia-Carbonero R; Arriaga YE; Verma U; Grothey A; Kappeler C; Miriyala A; Kalmus J; Falcone A; Zaniboni A
    Oncologist; 2019 Feb; 24(2):185-192. PubMed ID: 30190299
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety and efficacy of regorafenib in patients with treatment-refractory metastatic colorectal cancer in Turkey: the single-arm, open-label REGARD study.
    Dane F; Ozgurdal K; Yalçın Ş; Benekli M; Aykan NF; Yücel İ; Özkan M; Evrensel T; Sevinç A; Coskun HŞ; Sanli UA; Kara IO; Yumuk PF
    BMJ Open; 2020 Mar; 10(3):e027665. PubMed ID: 32220908
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A phase 2 study of panitumumab with irinotecan as salvage therapy in chemorefractory KRAS exon 2 wild-type metastatic colorectal cancer patients.
    Elez E; Pericay C; Valladares-Ayerbes M; Bando I; Safont MJ; Gallego J; Grávalos C; Arrivi A; Carrato A; Conde V; Ortiz MJ; López C; Alonso B; Ruiz de Mena I; Díaz-Rubio E; Tabernero J; Aranda E
    Br J Cancer; 2019 Aug; 121(5):378-383. PubMed ID: 31363167
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Large-Scale, Prospective Observational Study of Regorafenib in Japanese Patients with Metastatic Colorectal Cancer in a Real-World Clinical Setting.
    Yamaguchi K; Komatsu Y; Satoh T; Uetake H; Yoshino T; Nishida T; Yamazaki N; Takikawa H; Morimoto T; Chosa M; Sunaya T; Hamada Y; Muro K; Sugihara K
    Oncologist; 2019 Jul; 24(7):e450-e457. PubMed ID: 30606885
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Single-Agent Regorafenib in Metastatic Colorectal Cancer Patients with Any RAS or BRAF Mutation Previously Treated with FOLFOXIRI plus Bevacizumab (PREVIUM Trial).
    García-Alfonso P; Benavides M; Falcó E; Muñoz A; Gómez A; Sastre J; Rivera F; Montagut C; Salgado M; López-Ladrón A; López R; Ruiz de Mena I; Durán G; Aranda E;
    Oncologist; 2018 Nov; 23(11):1271-e128. PubMed ID: 30120161
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Survival, safety, and prognostic factors for outcome with Regorafenib in patients with metastatic colorectal cancer refractory to standard therapies: results from a multicenter study (REBECCA) nested within a compassionate use program.
    Adenis A; de la Fouchardiere C; Paule B; Burtin P; Tougeron D; Wallet J; Dourthe LM; Etienne PL; Mineur L; Clisant S; Phelip JM; Kramar A; Andre T
    BMC Cancer; 2016 Jul; 16():412. PubMed ID: 27389564
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Capecitabine plus temozolomide (CapTem): An alternative regimen to regorafenib as third-line setting in metastatic colorectal cancer?
    Ergun Y; Bal O; Dogan M; Uncu D
    J BUON; 2019; 24(6):2435-2441. PubMed ID: 31983117
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Regorafenib in Patients with Antiangiogenic-Naïve and Chemotherapy-Refractory Advanced Colorectal Cancer: Results from a Phase IIb Trial.
    Riechelmann RP; Leite LS; Bariani GM; Glasberg J; Rivelli TG; da Fonseca LG; Nebuloni DR; Braghiroli MI; Queiroz MA; Isejima AM; Kappeler C; Kikuchi L; Hoff PM
    Oncologist; 2019 Sep; 24(9):1180-1187. PubMed ID: 31175167
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of regorafenib in the treatment of metastatic colorectal cancer: A systematic review.
    Røed Skårderud M; Polk A; Kjeldgaard Vistisen K; Larsen FO; Nielsen DL
    Cancer Treat Rev; 2018 Jan; 62():61-73. PubMed ID: 29175677
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Regorafenib or rechallenge chemotherapy: which is more effective in the third-line treatment of metastatic colorectal cancer?
    Köstek O; Hacıoğlu MB; Sakin A; Demir T; Sarı M; Ozkul O; Araz M; Doğan AF; Demircan NC; Uzunoğlu S; Çiçin İ; Erdoğan B
    Cancer Chemother Pharmacol; 2019 Jan; 83(1):115-122. PubMed ID: 30374523
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Regorafenib in Chinese patients with metastatic colorectal cancer: Subgroup analysis of the phase 3 CONCUR trial.
    Xu J; Xu RH; Qin S; Pan H; Bai Y; Chi Y; Wang L; Bi F; Cheng Y; Liu T; Ma D; Shen L; Ba Y; Liang J; Wang X; Yau TCC; Ma BB; Yeh KH; Lin JK; Kappeler C; Shapiro J; Kalmus J; Li J
    J Gastroenterol Hepatol; 2020 Aug; 35(8):1307-1316. PubMed ID: 31900959
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Real-world safety and effectiveness of regorafenib in metastatic colorectal cancer: the French CORRELATE cohort.
    Metges JP; Genet D; Tougeron D; Ligeza C; Ducreux M; Borg C; Guimbaud R; Phelip JM; Dourthe LM; Kim S
    Future Oncol; 2021 Sep; 17(25):3343-3353. PubMed ID: 34011165
    [No Abstract]   [Full Text] [Related]  

  • 15. Propensity Score Analysis of Regorafenib Versus Trifluridine/Tipiracil in Patients with Metastatic Colorectal Cancer Refractory to Standard Chemotherapy (REGOTAS): A Japanese Society for Cancer of the Colon and Rectum Multicenter Observational Study.
    Moriwaki T; Fukuoka S; Taniguchi H; Takashima A; Kumekawa Y; Kajiwara T; Yamazaki K; Esaki T; Makiyama C; Denda T; Satake H; Suto T; Sugimoto N; Enomoto M; Ishikawa T; Kashiwada T; Sugiyama M; Komatsu Y; Okuyama H; Baba E; Sakai D; Watanabe T; Tamura T; Yamashita K; Gosho M; Shimada Y
    Oncologist; 2018 Jan; 23(1):7-15. PubMed ID: 28894015
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of Metastasectomy in the Multimodality Approach for
    Johnson B; Jin Z; Truty MJ; Smoot RL; Nagorney DM; Kendrick ML; Kipp BR; Grothey A
    Oncologist; 2018 Jan; 23(1):128-134. PubMed ID: 28904173
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Role of NRAS mutations as prognostic and predictive markers in metastatic colorectal cancer.
    Schirripa M; Cremolini C; Loupakis F; Morvillo M; Bergamo F; Zoratto F; Salvatore L; Antoniotti C; Marmorino F; Sensi E; Lupi C; Fontanini G; De Gregorio V; Giannini R; Basolo F; Masi G; Falcone A
    Int J Cancer; 2015 Jan; 136(1):83-90. PubMed ID: 24806288
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial.
    Grothey A; Van Cutsem E; Sobrero A; Siena S; Falcone A; Ychou M; Humblet Y; Bouché O; Mineur L; Barone C; Adenis A; Tabernero J; Yoshino T; Lenz HJ; Goldberg RM; Sargent DJ; Cihon F; Cupit L; Wagner A; Laurent D;
    Lancet; 2013 Jan; 381(9863):303-12. PubMed ID: 23177514
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of regorafenib in adult patients with metastatic osteosarcoma: a non-comparative, randomised, double-blind, placebo-controlled, phase 2 study.
    Duffaud F; Mir O; Boudou-Rouquette P; Piperno-Neumann S; Penel N; Bompas E; Delcambre C; Kalbacher E; Italiano A; Collard O; Chevreau C; Saada E; Isambert N; Delaye J; Schiffler C; Bouvier C; Vidal V; Chabaud S; Blay JY;
    Lancet Oncol; 2019 Jan; 20(1):120-133. PubMed ID: 30477937
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Real-world evidence of the safety and effectiveness of regorafenib in Taiwanese patients with metastatic colorectal cancer: CORRELATE Taiwan.
    Yeh KH; Yang TS; Hsu TC; Tzu-Liang Chen W; Chen HH; Teng HW; Lin BW; Kuan FC; Chiang FF; Duann CW; Li YS; Lin MT; Fiala-Buskies S; Ducreux M; Wang JY
    J Formos Med Assoc; 2021 Nov; 120(11):2023-2031. PubMed ID: 33422398
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.